Christopher Palmer has been an associate editor at MDedge News since 2017. When he's not tidying grammar, he writes short pieces about breaking FDA announcements and approvals, as well as journal articles. He proudly holds a BA in English and philosophy. Follow him on Twitter @cmacmpalm.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves Tecentriq plus Abraxane in breast cancer
- Author:
- Christopher Palmer
The immunotherapy regimen received accelerated approval for the treatment of PD-L1-positive triple-negative breast cancer in adults.
News
fMRI might help differentiate MDD and bipolar disorder
- Author:
- Christopher Palmer
Major depressive disorder and bipolar disorder appear to be associated with different underlying brain structures.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves liquid colchicine for gout
- Author:
- Christopher Palmer
Physicians can easily make dose adjustments with new form of colchicine, says Romeg Therapeutics.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
New BinaxNOW influenza test gets CLIA waiver
- Author:
- Christopher Palmer
The BinaxNOW Influenza A & B Card 2 test results are read by the DIGIVAL diagnostic reader, which is intended to remove subjectivity.
News
Brilinta reduces MACE in THEMIS trial
- Author:
- Christopher Palmer
Top-line results from AstraZeneca on the phase 3 THEMIS trial show that ticagrelor met its primary endpoint....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves combo Lonsurf for gastric and GEJ adenocarcinomas
- Author:
- Christopher Palmer
FDA approval was based on a boost in overall survival demonstrated in the phase 3 TAGS trial.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA clears test to monitor residual disease in CML
- Author:
- Christopher Palmer
The system can quantitate the molecular response of patients receiving tyrosine kinase inhibitor therapy.
News
Trametinib effectively treats case of giant congenital melanocytic nevus
- Author:
- Christopher Palmer
Intractable pain and pruritus resolved completely, which contributed to dramatic improvements in quality of life.
News
Switching long-acting injectables deemed safe in schizophrenia
- Author:
- Christopher Palmer
At 6 months, all-cause discontinuation was 30.4% and medication-related discontinuation was 9.2%
News
LGBTQ youth struggle in foster or unstable housing situations
- Author:
- Christopher Palmer
Analyses assessed risks including problems with mental health issues, in school, and with substance use.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
Impella RP shows higher mortality in postapproval study
- Author:
- Christopher Palmer
These results are interim and the FDA is continuing to evaluating them.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
New recall for CoaguChek test strips issued
- Author:
- Christopher Palmer
These CoaguChek XS PT test strips were distributed by Terrific Care and Medex but weren’t included in Roche Diagnostics’ original recall.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves generic Advair Diskus
- Author:
- Christopher Palmer
The approval hopefully will increase access for patients with asthma and COPD, according to the FDA.
News
Positive well-being may be ‘buffer against depression’ in adults with ASD
- Author:
- Christopher Palmer
“These results are consistent with research in the general population that shows well-being functions as a buffer or protective factor against...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA: Clozapine REMS modified
- Author:
- Christopher Palmer
Prescribers and pharmacies are required to be certified in the clozapine REMS program by Feb. 28.